Limited efficacy of VEGFR has also been reported, with progression-free survival in patients with Xp11.2 tRCC usually less than 1 year. The gene discussed is KDR; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.